IMMX Immix Biopharma, Inc.
9.490USD-1.56%Mkt Cap: 786.75M $P/E: —1d ago
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Aus…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.27BUSDP/E 30.7
$22.99BUSDP/E 14.5
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock Immix Biopharma’s latest clinical results showed strong patient responses to its lead CAR-T candidate as the biotech firm prepares for a planned regulatory filing in 2027. | ||
 Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial Immix Biopharma, Inc. (NASDAQ:IMMX) reported interim data from its NEXICART-2 Phase 2 clinical trial of NXC-201 in patients with relapsed or refractory AL amyloidosis. | ||
 Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive. | ||